Abstract
B-cell receptor (BCR) signaling is essential for chronic lymphocytic leukemia (CLL) cell survival. Many kinases in the BCR signaling pathway are being studied as potential therapeutic targets. Ibrutinib (PCI-32765) is a novel first-in-class selective inhibitor of Bruton tyrosine kinase. Preclinical evidence suggests that ibrutinib inhibits CLL cell survival and proliferation and affects CLL cell migration and homing. Early clinical data in patients with CLL and non-Hodgkin lymphoma is encouraging. It is likely that ibrutinib and other drugs targeting the BCR pathway will become an integral component of CLL therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 851-860 |
| Number of pages | 10 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 27 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2013 |
Keywords
- B-cell receptor inhibitor
- Bruton tyrosine kinase inhibitor
- Chronic lymphocytic leukemia
- Ibrutinib
- PCI-32765
ASJC Scopus subject areas
- Hematology
- Oncology